Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform

LEVERKUSEN, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors included Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital as well as existing investors, including New Enterprise Associates (NEA), 8VC, Amgen Ventures and Lux Cap

Click to view original post